GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Locust Walk Acquisition Corp (NAS:LWACW) » Definitions » Inventories, Other

LWACW (Locust Walk Acquisition) Inventories, Other : $0.00 Mil (As of Oct. 2020)


View and export this data going back to 2021. Start your Free Trial

What is Locust Walk Acquisition Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Locust Walk Acquisition's other inventories for the quarter that ended in Oct. 2020 was $0.00 Mil.

Locust Walk Acquisition Inventories, Other Historical Data

The historical data trend for Locust Walk Acquisition's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Locust Walk Acquisition Inventories, Other Chart

Locust Walk Acquisition Annual Data
Trend
Inventories, Other

Locust Walk Acquisition Semi-Annual Data
Oct20
Inventories, Other -

Locust Walk Acquisition Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Locust Walk Acquisition Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Locust Walk Acquisition Corp (NAS:LWACW) » Definitions » Inventories, Other
Comparable Companies
Traded in Other Exchanges
N/A
Address
200 Clarendon Street, 51st Floor, Boston, MA, USA, 02116
Website
https://www.locustwalkacquisitioncorp.com
Locust Walk Acquisition Corp is a blank check company.

Locust Walk Acquisition Headlines

From GuruFocus

Locust Walk Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option

By PRNewswire PRNewswire • 01-13-2021

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies

By Marketwired Marketwired • 05-27-2021

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

By Marketwired Marketwired • 07-22-2021

Locust Walk Acquisition Corp.'s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

By Marketwired Marketwired • 08-24-2021

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

By Marketwired Marketwired • 07-16-2021

Locust Walk Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on March 1, 2021

By PRNewswire PRNewswire • 02-23-2021

Locust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants

By Marketwired Marketwired • 06-03-2021

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

By Marketwired Marketwired • 08-26-2021